Analyst Alex Carchidi returns to update investors on the psychedelics industry. This is the full conversation of an interview originally published on Investing Experts.
(2:50) Industry's collapse and consolidation
(5:00) Compass Pathways timeline for clinical trials
(15:00) Super-risky biotech companies low on cash - don't bet on just 1 company
(21:20) Atai and Cybin's recent wins
(32:55) Ketamine clinics and viable business models